Maite Bourlon: Nivolumab Plus Cabozantinib in Metastatic Renal Cell Carcinoma
Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at the National Institute of Medical Sciences and Nutrition Salvador Zubirán, shared a post on X about recent paper she and colleagues co-authored, published in Frontiers in Oncology.
“Biggest RWD: Cabo/nivo 1st line kidney cancer
- N=333, 17 countries and 53 centers
- mFU 15.9m, mOS not reached, mPFS 33.7m
- ORR 58%, CR 6%
- Poor prognosis: ECOG, sarcomatoid, brain and bone mets
- ≥ G3 AE 37% (Hypertension and HFS).”
Title: Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Authors: Maria T. Bourlon, Luca Galli, Enrique Grande, Se Hoon Park, Bohuslav Melichar, Timothy J. Schieber, Maria José Juan-Fita, Yüksel Ürün, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Ugo De Giorgi, Jakub Kucharz, Esther Pérez Calabuig, Vincenza Conteduca, Tarek Taha, Pasquale Rescigno, Hussam Abu-Sini, Gian Paolo Spinelli, Ray Manneh Kopp, Alessia Salfi, Dipen Bhuva, Paola Valdez-Sandoval, Sofia Mendez-Bribiesca, Ondrej Fiala, Sebastiano Buti, Fernando Sabino Marques Monteiro, Aristotelis Bamias, Marwan Ghosn, Francesco Massari, Jawaher Ansari, Matteo Santoni
Read The Full Article at Frontiers in Oncology.
More Posts Featuring Maite Bourlon.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023